EGFR- and Integrin α V β 3 -Targeting Peptides as Potential Radiometal-Labeled Radiopharmaceuticals for Cancer Theranostics

• Published in: International journal of molecular sciences Vol. 25; no. 15
• Main Authors: Rodrigues Toledo, Cibele, Tantawy, Ahmed A, Lima Fuscaldi, Leonardo, Malavolta, Luciana, de Aguiar Ferreira, Carolina
• Format: Journal Article
• Language: English
• Published: Switzerland 05-08-2024
• Subjects: Animals; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - metabolism; Humans; Integrin alphaVbeta3 - metabolism; Neoplasms - diagnostic imaging; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - therapy; Peptides - chemistry; Peptides - therapeutic use; Precision Medicine - methods; Radiopharmaceuticals - chemistry; Radiopharmaceuticals - therapeutic use; Theranostic Nanomedicine - methods; integrin αVβ3; theranostics; cancer; EGFR
• EISSN: 1422-0067

The burgeoning field of cancer theranostics has witnessed advancements through the development of targeted molecular agents, particularly peptides. These agents exploit the overexpression or mutations of specific receptors, such as the Epidermal Growth Factor receptor (EGFR) and α
β
integrin, which are pivotal in tumor growth, angiogenesis, and metastasis. Despite the extensive research into and promising outcomes associated with antibody-based therapies, peptides offer a compelling alternative due to their smaller size, ease of modification, and rapid bioavailability, factors which potentially enhance tumor penetration and reduce systemic toxicity. However, the application of peptides in clinical settings has challenges. Their lower binding affinity and rapid clearance from the bloodstream compared to antibodies often limit their therapeutic efficacy and diagnostic accuracy. This overview sets the stage for a comprehensive review of the current research landscape as it relates to EGFR- and integrin α
β
-targeting peptides. We aim to delve into their synthesis, radiolabeling techniques, and preclinical and clinical evaluations, highlighting their potential and limitations in cancer theranostics. This review not only synthesizes the extant literature to outline the advancements in peptide-based agents targeting EGFR and integrin α
β
but also identifies critical gaps that could inform future research directions. By addressing these gaps, we contribute to the broader discourse on enhancing the diagnostic precision and therapeutic outcomes of cancer treatments.